Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | TTK | P33981 | 3/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25450985 | 0.99 | SYK (0.32) | SYKTTKMAPKAPK5PDE4BPDE4D | |
| SCHEMBL25450974 | 0.99 | SYK (0.32) | SYKTTKMAPKAPK5PDE4BPDE4D | |
| Formic Acid SCHEMBL25173520 | 0.97 | ADRA2B (0.31) | SYKTTKMAPKAPK5 | |
| Formic Acid SCHEMBL25170441 | 0.96 | ADRA2B (0.31) | SYKTTKMAPKAPK5 | |
| SCHEMBL25451055 | 0.96 | PTK6 (0.32) | SYKTTKMAPKAPK5PDE4BPDE4D | |
| Trifluoroacetic Acid SCHEMBL30385284 | 0.95 | TTK (0.30) | SYKTTK | |
| Trifluoroacetic Acid SCHEMBL30385662 | 0.92 | TTK (0.32) | TTKPTK6 | |
| SCHEMBL22123676 | 0.91 | SYK (0.36) | SYKTTKMAPKAPK5PDE4BPDE4D | |
| SCHEMBL22123913 | 0.91 | SYK (0.36) | SYKTTKMAPKAPK5PDE4BPDE4D | |
| SCHEMBL22123449 | 0.91 | SYK (0.36) | SYKTTKMAPKAPK5PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | SYK 256/4885TTK 4336/4885MAPKAPK5 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.